Milestone Pharmaceuticals is focused on developing innovative treatments for acute cardiovascular conditions, particularly paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR). Their lead investigational product, etripamil, is a novel non-dihydropyridine calcium channel blocker that is administered as a nasal spray. This delivery method is designed for self-administration in non-hospital settings, allowing patients to manage their episodes of PSVT and AFib-RVR at home. The company aims to address the existing therapeutic gap for rapid termination of these conditions, providing patients with a convenient and effective treatment option.

Milestone Pharmaceuticals is currently conducting a comprehensive clinical trial program to evaluate the safety and efficacy of etripamil. Their Phase 3 clinical program includes multiple trials that assess the drug's performance in at-home settings without the need for medical supervision. The trials are designed to gather data on the drug's effectiveness in terminating episodes of PSVT and AFib-RVR, as well as its safety profile. Through these efforts, Milestone aims to contribute to the scientific understanding of these cardiovascular conditions and improve patient outcomes by offering a new therapeutic option for managing acute episodes.

Canada

Milestone Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of etripamil, a Phase 3 clinical-stage program, for the treatment of cardiovascular indications. Milestone Pharmaceuticals operates in Canada and the United States. 

Cardiovascular Diseases

Milestone Pharmaceuticals

Paroxysmal supraventricular tachycardia

Etripamil, the Company's lead investigational product, is designed to be a rapid-response therapy for episodic cardiovascular conditions. The novel calcium channel blocker is self-administered via a nasal spray, which has the potential to shift the current treatment paradigm for many patients with PSVT from the emergency department to the at-home setting. Milestone is conducting a comprehensive development program for etripamil, with Phase 3 trials underway in PSVT, and plans to commence a Phase 2 proof-of-concept trial in patients with atrial fibrillation with rapid ventricular rate.

CARDAMYST (Etripamil) (calcium channel blocker)

Atrial fibrillation

Etripamil (calcium channel blocker)

Angina

Coronary artery disease

Etripamil, the Company's lead investigational product, is designed to be a rapid-response therapy for episodic cardiovascular conditions. The novel calcium channel blocker is self-administered via a nasal spray, which has the potential to shift the current treatment paradigm for many patients with PSVT from the emergency department to the at-home setting. Milestone is conducting a comprehensive development program for etripamil, with Phase 3 trials underway in PSVT, and plans to commence a Phase 2 proof-of-concept trial in patients with atrial fibrillation with rapid ventricular rate.

Milestone Pharmaceuticals

Company Details